肾细胞癌中177Lu-PSMA放射性配体快速从肿瘤洗脱
本文报道一例转移性肾细胞癌患者接受177Lu-PSMA I&T放射性配体治疗的 experience,但影像学发现意外显示177Lu-PSMA从肿瘤中快速洗脱;此前文献尚未报道过肾细胞癌患者的PSMA放射性配体治疗。
要点
- PSMA在肾细胞癌新生血管中过表达,PSMA PET显像对肾细胞癌有诊断价值。
- 本文首次报道一例转移性肾细胞癌患者接受177Lu-PSMA I&T放射性配体治疗。
- 治疗后影像意外显示177Lu-PSMA从肿瘤中快速洗脱。
核心结论
- 本文报道一例转移性肾细胞癌患者接受177Lu-PSMA I&T放射性配体治疗,影像学显示177Lu-PSMA从肿瘤中快速洗脱这一意外发现。
研究设计与样本
- 本文为个案报道,报告一例转移性肾细胞癌患者接受177Lu-PSMA I&T放射性配体治疗的经验。
主要发现
- 该例转移性肾细胞癌患者接受177Lu-PSMA I&T放射性配体治疗后,影像学显示177Lu-PSMA从肿瘤中快速洗脱。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The role of prostate-specific membrane antigen (PSMA) targeted molecular imaging and radionuclide therapy in prostate cancer is well known. PSMA is also overexpressed in the neovasculature of a number of solid tumors, including renal cell carcinoma (RCC). Several studies have demonstrated the diagnostic utility of PSMA PET imaging in the setting of RCC. To date, no PSMA radioligand therapy of RCC patient has been reported according to literature. Here, we report our experience treating a patient with metastatic RCC with 177 Lu-PSMA I&T radioligand therapy, but unexpected imaging findings with rapid washout of 177 Lu-PSMA from the tumor.
引用
- Zhang J, Schuchardt C, Chen X, et al. Rapid Tumor Washout of 177 Lu-PSMA Radioligand in Renal Cell Carcinoma. Clin Nucl Med. 2023. PMID: 37276536. doi:10.1097/RLU.0000000000004725
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。